Press coverage about Accuray (NASDAQ:ARAY) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Accuray earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 44.9332772499235 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Accuray (NASDAQ ARAY) opened at $4.25 on Friday. The firm has a market capitalization of $347.77, a price-to-earnings ratio of -12.14 and a beta of 1.28. Accuray has a 1-year low of $3.60 and a 1-year high of $6.00. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.02. The business had revenue of $91.00 million during the quarter, compared to the consensus estimate of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. Accuray’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.12) earnings per share. equities analysts anticipate that Accuray will post -0.2 EPS for the current fiscal year.

Several research analysts have commented on ARAY shares. Lake Street Capital initiated coverage on shares of Accuray in a research report on Thursday, November 30th. They set a “buy” rating and a $10.00 price objective for the company. BidaskClub downgraded shares of Accuray from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. J P Morgan Chase & Co downgraded shares of Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 price target for the company. in a report on Wednesday, December 13th. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a report on Tuesday, October 24th. Finally, Cowen reiterated a “buy” rating and set a $9.00 price target on shares of Accuray in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $6.82.

In other Accuray news, CFO Kevin Waters sold 7,154 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $5.06, for a total transaction of $36,199.24. Following the sale, the chief financial officer now owns 335,087 shares of the company’s stock, valued at $1,695,540.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kelly Londy sold 99,136 shares of the company’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $4.24, for a total transaction of $420,336.64. The disclosure for this sale can be found here. Insiders sold 125,549 shares of company stock valued at $550,135 over the last 90 days. 3.90% of the stock is currently owned by company insiders.

WARNING: “Accuray (ARAY) Earns Daily Media Impact Rating of 0.12” was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Insider Buying and Selling by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with's FREE daily email newsletter.